Hercules Capital

Congratulations to Hercules Capital portfolio company Armis on closing $200 million in financing to build a multi-generational cybersecurity company, fuel strong organic product innovation and global go-to-market programs, and take advantage of game changing inorganic growth opportunities that may arise.

Hercules Capital (NYSE: HTGC) is pleased to announce that its Board of Directors has declared a third quarter 2024 total cash distribution of $0.48 per share. The total cash distribution is comprised of a $0.40 per share base distribution and an $0.08 per share supplemental distribution. https://lnkd.in/gcPph8SM

Hercules Capital, Inc. (NYSE: HTGC) today announced that it has scheduled its third quarter 2024 financial results conference call for Wednesday, October 30, 2024, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. Read more: https://lnkd.in/eX9SMKCc

Congratulations to Hercules portfolio company Heron Therapeutics, Inc. on achieving this milestone contributing to the continued progress of ZYNRELEF®.

Hercules Capital (Lesya Kulchenko, Tyler W. and Team) is thrilled to support Reveleer (Jay Ackerman, Erin Lafferty, Vindya Dayananda and Team) as they continue to enhance their capabilities to solve important challenges faced by payer and provider organizations. Congrats to everyone involved! View the press release here: https://lnkd.in/gD9_Antp

In June 2024, Semperis announced a $125 million investment led by J.P. Morgan and Hercules Capital, along with the addition of new executives who bring IPO and public company experience. Semperis continues its rapid growth to further invest in product innovation and support a rapidly expanding global customer base.   ICYMI: Check out what else The Hudson Reporter has to say about Semperis’ recent raise, executive appointments, and overall growth. https://lnkd.in/g_jPNhth   "Semperis is a clear leader in the urgently needed area of identity system defense, with machine-learning-based attack prevention, detection, and response," said Scott Bluestein, CEO and CIO at Hercules Capital. "Leading organizations around the world depend on Semperis to safeguard their hybrid Active Directory environment, which is foundational to the IT infrastructure and heavily targeted by attackers."

Hercules fielded a foursome at Life Science Cares Boston's annual Mini Golf for Good Tournament in Tech Square earlier this month! The event brings life science professionals together in support of LSC's grant-giving to nonprofits addressing the needs for food and shelter, education, and economic sustainability for the community’s most vulnerable neighbors. Learn more about Life Science Cares, here: https://lnkd.in/gvuX6zx

Hercules Capital provides companies across the life sciences and healthcare sectors with highly flexible, strategic growth capital that can benefit almost any business model, from drug development to digital health and value-based care. We are inspired by the countless clinical achievements, innovations, and unwavering persistence of the companies in our ecosystem. Learn more about our practice in our latest Life Sciences Update: https://lnkd.in/e6_8qrC8

Hercules Capital's Technology Team helps innovative venture and private equity-backed companies accelerate innovation, enhance product capabilities, extend their sales and marketing runway, and expand into new markets with non-dilutive, growth financing solutions. Connect with us to learn more about the fit and timing of venture lending for your company: https://lnkd.in/eUWWwN4 #saas #software #technology #enterprise #cybersecurity #spacetech #internet #ai #robotics

Hercules Capital's Life Sciences Team helps transformative biotechnology, pharmaceutical, and healthcare services companies prepare for strategic partnerships, expand clinical development, invest in R&D, and navigate value inflection points with non-dilutive, growth financing solutions. Connect with us to learn more about the fit and timing of venture lending for your company: https://lnkd.in/dVjWaV6 #lifesciences #pharma #healthcare #biotech #drugdiscovery #medicaldevices